辛伐他汀治疗慢性阻塞性肺病患者的临床疗效观察-现代医学

辛伐他汀治疗慢性阻塞性肺病患者的临床疗效观察

单位：太仓市中医医院呼吸科, 江苏太仓 215400

关键词：辛伐他汀慢性阻塞性肺疾病高敏C-反应蛋白肿瘤坏死因子白介素-6 8-异前列腺素

分类号：R563.3

出版年·卷·期（页码）：2017·36·第四期（575-578）

摘要：

目的：在常规治疗基础上增加辛伐他汀，观察其对慢性阻塞性肺疾病（COPD）患者血清炎症因子（hsCRP、TNF-α、IL-6、8-iso-PG）、动脉血气分析、肺功能、六分钟步行（6MWD）的治疗影响，评价辛伐他汀对COPD的治疗价值。方法：选取62例慢性阻塞性肺病患者，将其随机分为两组对照组和观察组，对照组30例患者接受常规治疗，观察组32例患者在此基础上加用辛伐他汀治疗，疗程3个月，对比两组患者治疗前后血清中hs-CRP、IL-6、TNF-α、8-iso-PG水平、动脉血气分析、肺功能、6MWD。结果：治疗后，两组血清中hs-CRP、IL-6、TNF-α、8-iso-PG水平均较前下降（P < 0.05），但辛伐他汀治疗组降低更明显（P < 0.05）。治疗后，PaO₂、6MWD较前增高（P < 0.05）；而对照组无明显改变（P > 0.05），两组比较有显著差异（P < 0.05）。而两组治疗后肺功能未见明显差异（P > 0.05）。结论：辛伐他汀能降低COPD患者血清炎症因子水平，改善临床症状，但对肺功能无明显改善作用。

Objective: To investigate the effects of simvastatin on pulmonary function, arterial blood gas, 6-minute walking distance(6MWD) and the levels of inflammatory factors in patients with Chronic obstructive pulmonary disease (COPD). Methods: Sixty-two patients with COPD were recruited from September 2014 to April 2016. The patients were randomly divided into two groups:the simvastatin treatment group(n=32) and the control group (n=30), the control group received conventional therapy according to COPD. The simvastatin treatment group received extra simvastatin besides conventional therapy in control group. They were treated for 3 months respectively. High-sensitivity C-reactive protein(hs-CRP), tumor necrosis factor-α(TNF-α), interleukin-6(IL-6), 8-isoprostane(8-iso-PG) in plasma, The lung function, arterial blood gases, 6MWD, serum samples were assayed in all cases before and after the treatment.Results: After treatment, The level of hs-CRP, TNF-α, IL-6, 8-iso-PG in plasma was decreased in the two groups(P<0.05), but the declined level in the simvastatin treatment group was more obvious than that in the control group (P<0.05). After treatment, the PaO₂, 6MWD were significantly increased in simvastatin treatment group (P<0.05), however, there had no significant difference in control group(P>0.05), the two groups had a significant difference(P<0.05). Forced expiratuary volume in the first second(FEV₁), Forced vital capacity (FVC) in two groups had no significant difference(P>0.05).Conclusion: Simvastatin reduces the level of serum inflammatory factors in patients with COPD, improves clinical symptoms, but does not significantly improve lung function.

参考文献：

[1] WRIGHT JL,LEVY RD,CHURG A.Pulmnonary hypertension in chronic obstructive pulmonary disease:current theories of pathogenesis and their implications for treatment[J].Thorax,2005,60(7):605-609.
[2] 王勍.多靶点抗炎治疗老年慢性阻塞性肺疾病急性加重期临床研究[J].中国全科医学,2010,13(16):1760-1762.
[3] 翁翠萍,王清云,顾雪峰.慢性阻塞性肺病患者急性发作期TNF-α和CRP测定水平及临床意义[J].淮海医药,2007,25(6):523-524.
[4] PETERSON K M,ALY A,LERMAN A,et al.Improved survival of mesenchymal stromal cell after hypoxia preconditioning:role of oxidative stress[J].Life Sci,2011,88(1-2):65-73.
[5] KATSIKI N,WIERZBICKI A S,MIKHAILIDIS D P.Pulmonary arterial hypertension and statins:an update[J].Curr Opin Cardiol,2011,26(4):322-326.
[6] NISHIMURA T,VASZAR L T,FAUL J L,et al.Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells[J].Circulation,2003,108(13):1640-1645.
[7] LEE J H,LEE D S,KIM E K,et al.Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs[J].Am J Respir Crit Care,2005,172(8):987-993.
[8] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中国医学前沿杂志:电子版,2014,6(2):67-81.
[9] Nishimura T,Faul J L,Berry G J,et al.Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats[J].Am J Respir Crit Care Med,2002,166(10):1403-1408.
[10] RAKOTONIAINA Z,GUERARD P,LIRUSSI F,et al.The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect:comparison of pravastatin and atorvastatin[J].Naunyn Schmiedebergs Arch Pharmacol,2006,374(3):195-206.
[11] KAO P N.Simvastatin treatment of pulmonary hypertension:an observational case series[J].Chest,2005,127(4):1446-1452.
[12] SOUZACOSTA DC,FIGUEIREDOLOPES L,ALVESFILHO J C,et al.Protective effects of atorvastatin in rat models of acute pulmonary embolism:involvement of matrix metalloproteinase-9[J].Crit Care Med,2007,35(35):239-245.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录